Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
N. Pham (Hanoi, Vietnam), Q. Do (Hanoi, Vietnam), T. Ta (Hanoi, Vietnam), D. Nguyen (Hanoi, Vietnam), D. Do (Hanoi, Vietnam). Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients. 1765

Member's Comments

No comment yet.

Related content which might interest you: Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Radio(chemo)therapy in locally advanced nonsmall cell lung cancer Source: Eur Respir Rev 2015; 25: 65-70 Year: 2016 Advanced non-small cell lung cancer in elderly patients Source: Breathe 2012; 9: 26-34 Year: 2012 C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009 Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center. Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Management of stage I and II nonsmall cell lung cancer Source: Eur Respir J 2017; 49(1): 1600764; DOI: 10.1183/13993003.00764-2016 Year: 2017 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011